To obtain hints towards the nature of the recognized antigens, we in silico subjoined TCR CDR3 sequences, which have been experimentally verified to recognize melanoma differentiation (MDA) and cancer testis antigens (CTA), i.e., gp100, MAGEA1, MART-1, or NY-ESO-1, derived peptide/MHC complexes (Fig. 5b and Suppl. The gene discussed is MAGEA1; the disease is melanoma.